 This Phase 3 study is intended to demonstrate superiority of either Sotagliflozin high dose or low dose versus placebo on glycosylated hemoglobin A1C A1C reduction at Week 24 when used as an adjunct in adult patients with type 1 diabetes mellitus T1D who have inadequate glycemic control with insulin therapy. 